HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Abstract
Skull base chordomas are challenging tumors due to their deep surgical location and resistance to conventional radiotherapy. Chemotherapy plays a marginal role in the treatment of chordoma resulting from lack of preclinical models due to the difficulty in establishing tumor cell lines and valuable in vivo models. Here, we established a cell line from a recurrent clival chordoma. Cells were cultured for more than 30 passages and the expression of the chordoma cell marker brachyury was monitored using both immunohistochemistry and Western blot. Sensitivity of chordoma cells to the inhibition of specific signaling pathways was assessed through testing of a commercially available small molecule kinase inhibitor library. In vivo tumorigenicity was evaluated by grafting chordoma cells onto immunocompromised mice and established tumor xenografts were treated with rapamycin. Rapamycin was administered to the donor patient and its efficacy was assessed on follow-up neuroimaging. Chordoma cells maintained brachyury expression at late passages and generated xenografts closely mimicking the histology and phenotype of the parental tumor. Rapamycin was identified as an inhibitor of chordoma cell proliferation. Molecular analyses on tumor cells showed activation of the mammalian target of rapamycin signaling pathway and mutation of KRAS gene. Rapamycin was also effective in reducing the growth of chordoma xenografts. On the basis of these results, our patient received rapamycin therapy with about six-fold reduction of the tumor growth rate upon 10-month follow-up neuroimaging. This is the first case of chordoma in whom chemotherapy was tailored on the basis of the sensitivity of patient-derived tumor cells.
AuthorsLucia Ricci-Vitiani, Daniele Runci, Quintino Giorgio D'Alessandris, Tonia Cenci, Maurizio Martini, Federico Bianchi, Giulio Maira, Louis Stancato, Ruggero De Maria, Luigi Maria Larocca, Roberto Pallini
JournalNeoplasia (New York, N.Y.) (Neoplasia) Vol. 15 Issue 7 Pg. 773-82 (Jul 2013) ISSN: 1476-5586 [Electronic] United States
PMID23814489 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • Sirolimus
Topics
  • Adult
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Chordoma (diagnosis, drug therapy, genetics)
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Mutation
  • Primary Cell Culture
  • Proto-Oncogene Proteins (genetics)
  • Proto-Oncogene Proteins B-raf (genetics)
  • Proto-Oncogene Proteins p21(ras)
  • Sirolimus (pharmacology, therapeutic use)
  • Skull Base Neoplasms (diagnosis, drug therapy, genetics)
  • Treatment Outcome
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays
  • ras Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: